Home/Pipeline/APG-3785

APG-3785

Advanced Solid Tumors

PreclinicalActive

Key Facts

Indication

Advanced Solid Tumors

Phase

Preclinical

Status

Active

Company

Ascentage Pharma Group

About Ascentage Pharma Group

Ascentage Pharma Group is a China-based, publicly traded biotech with a mission to develop transformative therapies by targeting apoptosis and autophagy pathways. The company has established a robust clinical pipeline, with multiple assets in global trials for various cancers, positioning its lead candidates as potential best-in-class agents. Its integrated strategy combines proprietary target discovery with clinical development and manufacturing to advance novel treatments for global markets. Key achievements include advancing several programs into mid- and late-stage clinical development and building a strong intellectual property portfolio around its core platform.

View full company profile

Therapeutic Areas

Oncology Virology

Other Advanced Solid Tumors Drugs

Drug	Company	Phase	Status
NT219	Purple Biotech	Phase 1/2	Active
INDP-101	Indaptus Therapeutics	Phase 1	Active, not recruiting
PM14	PharmaMar	Phase 1/2	Active
Ecubectedin (PM54)	PharmaMar	Phase 1	Active
AP-202	Advance Pharmaceutical	Phase 1/2	Active, dose expansion
BI-1808	BioInvent International	Phase 1/2a	Active
GIGA-564	GigaGen	Phase 1	Active
Venadaparib (IDX-1197)	Idience	Phase 1a	Completed
VET3-TGI	KaliVir Immunotherapeutics	Phase 1	Active
IT-141 (Etoposide IVECT™)	Intezyne	Phase 1	Active
NC318	NextCure	Phase 1/2	Discontinued (Monotherapy)
VisAcT (18F-AraG) Imaging in Solid Tumors	CellSight Technologies	Phase 1/2	Active